Other equities research analysts have also recently issued research reports about the stock. HC Wainwright reaffirmed a buy rating and set a $14.00 price objective on shares of Cytosorbents in a research report on Wednesday. ValuEngine raised Cytosorbents from a sell rating to a hold rating in a research note on Tuesday, January 9th. Cowen set a $9.00 target price on Cytosorbents and gave the stock a buy rating in a research note on Thursday, March 8th. Finally, B. Riley reissued a buy rating and set a $11.25 target price on shares of Cytosorbents in a research note on Thursday, January 25th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of Buy and an average price target of $11.05.
CTSO traded up $0.15 on Wednesday, hitting $8.05. 157,566 shares of the stock were exchanged, compared to its average volume of 164,265. Cytosorbents has a 12 month low of $7.80 and a 12 month high of $8.05. The company has a quick ratio of 2.54, a current ratio of 6.16 and a debt-to-equity ratio of 0.68. The stock has a market capitalization of $240.25 million, a price-to-earnings ratio of -25.16 and a beta of -0.08.
In other Cytosorbents news, CFO Kathleen P. Bloch sold 10,000 shares of the business’s stock in a transaction dated Wednesday, February 21st. The stock was sold at an average price of $8.00, for a total transaction of $80,000.00. Following the completion of the transaction, the chief financial officer now owns 268,870 shares of the company’s stock, valued at $2,150,960. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Kathleen P. Bloch sold 11,176 shares of the business’s stock in a transaction dated Thursday, March 15th. The stock was sold at an average price of $8.25, for a total value of $92,202.00. Following the transaction, the chief financial officer now directly owns 261,246 shares of the company’s stock, valued at approximately $2,155,279.50. The disclosure for this sale can be found here. In the last three months, insiders have sold 22,400 shares of company stock valued at $182,300. Insiders own 6.90% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in CTSO. Wells Fargo & Company MN increased its stake in shares of Cytosorbents by 182.3% in the fourth quarter. Wells Fargo & Company MN now owns 20,929 shares of the medical research company’s stock valued at $136,000 after buying an additional 13,515 shares during the period. Goldman Sachs Group Inc. acquired a new position in shares of Cytosorbents in the fourth quarter valued at approximately $146,000. Fortaleza Asset Management Inc. increased its stake in shares of Cytosorbents by 60.9% in the fourth quarter. Fortaleza Asset Management Inc. now owns 37,615 shares of the medical research company’s stock valued at $244,000 after buying an additional 14,240 shares during the period. Tibra Equities Europe Ltd acquired a new position in shares of Cytosorbents in the first quarter valued at approximately $362,000. Finally, BlueCrest Capital Management Ltd acquired a new position in shares of Cytosorbents in the fourth quarter valued at approximately $396,000. 10.53% of the stock is owned by institutional investors.
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.